FDA Approves Apixaban for New Use

The U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) as a preventative measure against potential pulmonary embolism-causing blood clots for patients who have undergone hip or knee replacement therapy, according to a news release.

Previously, Eliquis was only approved to reduce the risk of stroke and blood clots for patients with atrial fibrilliation not caused by a heart valve problem.

IV sets recalled due to missing safety component

ICU Medical has issued a Class I recall for certain 150 mL IV Gravity Burette Sets after discovering some devices…

6 recent Medline moves

Medline has struck a series of new and expanded partnerships with health systems in recent months, reinforcing its position as…

5-state provider taps Medline as prime vendor

Kentucky-based Signature HealthCare has entered a prime vendor agreement with Medline. The agreement, signed in July 2025, gives Signature HealthCare…

FDA Approves Apixaban for New Use

More Articles on FDA Approvals:

Next Up in Supply Chain

IV sets recalled due to missing safety component

6 recent Medline moves

5-state provider taps Medline as prime vendor

More Articles on FDA Approvals:

Why efficiency is becoming the new growth strategy for ambulatory care organizations

Next Up in Supply Chain

IV sets recalled due to missing safety component

6 recent Medline moves

5-state provider taps Medline as prime vendor

Join the 500,000+ healthcare executives who start their day with Becker’s